Outcomes of Brentuximab Vedotin in Cutaneous T-Cell Lymphoma: A Middle Eastern Real-World Study

Published: 3 August 2026| Version 1 | DOI: 10.17632/7fbh39f94j.1
Contributor:
Ahmad AlSarraf

Description

Supplemental material of our study covering prior treatment exposure before initiation of brentuximab vedotin and definitions of clinical endpoints

Files

Categories

Brentuximab Vedotin, Middle East, Cutaneous T-Cell Lymphoma, Kuwait

Licence